HEALTHCARE PROFESSIONAL REQUEST CENTER — This site is intended for U.S. Healthcare Professionals only
Pancreaze Engage logo

Registration

Complete the following three sections below to create your all-access account
 

1. Profile information

All fields are required unless specified

2. Professional Information

3. Consent and releases

I declare that I am a licensed Healthcare Professional and I want to register for the PANCREAZE Engage Healthcare Professional Request Center. This declaration authorizes VIVUS to contact me and confirm and validate the professional information provided during the registration process.

 

I understand that by clicking the “SUBMIT” button below, and registering for the PANCREAZE Engage Healthcare Professional Request Center, and by using this website, I am authorizing VIVUS or its designee to contact me by telephone, direct mail or email. For more information about VIVUS’ privacy practices please view the Privacy Policy.

Log in and use of PANCREAZE Engage Healthcare Professional Request Center is
governed by the VIVUS Terms of Use and Privacy Policy.

Return to homepage

Indication

PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

Important Safety Information

Fibrosing Colonopathy: Associated with high doses, usually over prolonged use and in pediatric patients with cystic fibrosis. Colonic stricture reported in pediatric patients less than 12 years of age with dosages exceeding 6,000 lipase units/kg/meal. Monitor during treatment for progression of preexisting disease. Do not exceed the recommended dosage, unless clinically indicated.

Hyperuricemia has been reported with high dosages; consider monitoring blood uric acid levels in patients with gout, renal impairment, or hyperuricemia.

Irritation of the oral mucosa may occur due to loss of protective enteric coating on the capsule contents.

The presence of porcine viruses that might infect humans cannot be definitely excluded.

Monitor patients with known reactions to proteins of porcine origin. If symptoms occur, initiate appropriate medical management; consider the risks and benefits of continued treatment.

 
Please click here for the PANCREAZE Medication Guide and Full Prescribing Information.

Important Safety Information

Fibrosing Colonopathy: Associated with high doses, usually over prolonged use and in pediatric patients with cystic fibrosis. Colonic stricture reported in pediatric patients less than 12 years of age with dosages exceeding 6,000 lipase units/kg/meal. Monitor during treatment for progression of preexisting disease. Do not exceed the recommended dosage, unless clinically indicated.

VIEW ALL +